MyMyelomaTeam

Great question — and the honest answer is: it depends. Neither is universally "better." Both target BCMA, a protein found on myeloma cells, but they work differently and suit different situations.

CAR-T Cell Therapy (Carvykti or Abecma)
- Generally produces deeper, longer-lasting remissions
- A one-time custom infusion made Show Full Answer

Great question — and the honest answer is: it depends. Neither is universally "better." Both target BCMA, a protein found on myeloma cells, but they work differently and suit different situations.

CAR-T Cell Therapy (Carvykti or Abecma)
- Generally produces deeper, longer-lasting remissions
- A one-time custom infusion made from your own T cells
- 1 in 3 people with relapsed myeloma stayed in remission for 5+ years after Carvykti
- Takes weeks to manufacture, so not ideal if myeloma is progressing rapidly
- Requires staying near a specialized center for about a month
- Serious side effects can include cytokine release syndrome (CRS) and neurological issues Tecvayli (Teclistamab)
- An "off-the-shelf" subcutaneous injection — no manufacturing wait time
- Overall response rate of 62% in clinical trials
- Better option when treatment is needed urgently
- Requires ongoing long-term administration
- Can cause CRS and increases infection risk due to immune suppression How doctors typically choose between them:

- Urgency: If myeloma is progressing fast, Tecvayli can start immediately
- Logistics: CAR-T requires time, travel, and staying near a specialist center
- Sequencing: Many oncologists prefer CAR-T first, with bispecifics like Tecvayli as a follow-up option if relapse occurs later

The best path really comes down to personal circumstances — disease speed, overall health, and what's accessible. A conversation with your hematologist-oncologist about your specific situation is the most important next step.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

33% Stay Myeloma-Free 5 Years After CAR T-Cell Therapy

Myeloma Treatment Journey: From First Line to Fourth Line